Edition:
United States

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

39.97USD
3:59pm EST
Change (% chg)

$-0.88 (-2.15%)
Prev Close
$40.85
Open
$40.84
Day's High
$41.00
Day's Low
$38.54
Volume
165,043
Avg. Vol
185,170
52-wk High
$42.72
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China
Tuesday, 5 Dec 2017 08:30am EST 

Dec 5 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA.ARENA PHARMACEUTICALS INC - C-BRIDGE CAPITAL HAS INVESTED $50 MILLION TO FUND EVEREST MEDICINES LIMITED.ARENA PHARMACEUTICALS - AS PER AGREEMENT, CO WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.ARENA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ARENA IS ELIGIBLE TO RECEIVE UP TO $212 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Arena Pharmaceuticals reports Q3 loss per share $0.86
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.86.Q3 revenue $7.9 million.Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​.Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​.  Full Article

Arena Pharmaceuticals Q2 loss per share $0.77
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results.Q2 revenue $6.5 million versus I/B/E/S view $5.5 million.Q2 loss per share $0.77.Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals - ‍at June 30, cash and cash equivalents totaled $130.8 million; about 31.8 million shares of arena common stock were outstanding​.  Full Article

Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share
Wednesday, 12 Jul 2017 08:11pm EDT 

July 12 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 6.25 million common shares priced at $24.00per share.Gross proceeds from offering are expected to be $150.0 million.  Full Article

Arena Pharmaceuticals says has cash and cash equivalents as of June 30 of $130.8 mln
Tuesday, 11 Jul 2017 05:28pm EDT 

July 11 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals - Cash and cash equivalents as of June 30, 2017 of $130.8 million, which includes about $0.2 million of cash held by beacon discovery.  Full Article

Arena Pharmaceuticals announces proposed public offering of common stock
Tuesday, 11 Jul 2017 04:05pm EDT 

July 11 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces proposed public offering of common stock.Arena Pharmaceuticals Inc - ‍intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering​.  Full Article

Arena Pharmaceuticals reports topline phase 2 results for Ralinepag
Monday, 10 Jul 2017 04:01pm EDT 

July 10 (Reuters) - Arena Pharmaceuticals Inc ::Arena pharmaceuticals reports positive topline phase 2 results for Ralinepag in patients with pulmonary arterial hypertension.Safety data of phase 2 trial for ralinepag consistent with other drugs acting through prostacyclin receptor-mediated effects.Says Ralinepag also demonstrated numerical improvement in 6-minute walk distance.Primary efficacy analysis successful in phase 2 trial for Ralinepag; significant improvement in pulmonary vascular resistance.  Full Article

Arena Pharmaceuticals says shareholders and board approve reverse stock split
Wednesday, 14 Jun 2017 04:01pm EDT 

June 14 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals announces shareholders and board of directors approve reverse stock split.Arena Pharmaceuticals Inc - stockholders voted to approve proposal authorizing reverse stock split of common shares at an exchange ratio of 1-for-10.  Full Article

Arena Pharmaceuticals reports Q1 loss per share $0.09
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals provides corporate update and reports first quarter 2017 financial results.Q1 loss per share $0.09.Q1 revenue $6.6 million versus I/B/E/S view $8.1 million.Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc says Ralinepag phase 2 study results expected in July.  Full Article

Arena Pharmaceuticals prices 60 mln shares of common stock at price of $1.15/share
Monday, 17 Apr 2017 10:15pm EDT 

April 17 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces pricing of public offering of common stock.Priced an underwritten public offering of 60 million shares of its common stock, at a price of $1.15 per share.  Full Article

BRIEF-Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

* ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA